Navidea Biopharmaceuticals Inc. (NAVB) 1.60 $NAVB
Achillion Soars on 6 Week HCV Cure When Used with Gilead's Sofosbuvir - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Feb 09, 2:38PM CST
Achillion shares are up nearly double digits today thanks to promising results for its ACH-3102 when used in combination with Gilead Sciences' (GILD) sofosbuvir.
NAVB: 1.60 (unch), AUPH: 3.46 (+0.01), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20)
Navidea reports preliminary 2014 revenue
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 7:07AM CST
NAVB: 1.60 (unch)
Navidea Reports Preliminary 2014 Revenue; Provides Update on New Commercial Strategy
Business Wire - Mon Feb 09, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today reports preliminary, unaudited total revenue of $6.3 million for the year ended December 31, 2014, including total product revenue from Lymphoseek(R) (technetium Tc 99m tilmanocept) injection of $4.2 million. For the three months ended December 31, 2014, Navidea reports preliminary, unaudited total revenue of $2.2 million, including total product revenue from Lymphoseek of $1.5 million. Total revenue includes product revenue from sales of Lymphoseek to the Company's distribution partner, grant revenue and revenue generated from business development activities; however, it should be noted product revenue recognized by Navidea represents only a portion of the total brand revenue generated by the distribution partner on sales of Lymphoseek to end customers. Navidea's gross profit is expected to be $4.7 million for the year ended December 31, 2014 and $1.9 million for the three months ended December 31, 2014.
NAVB: 1.60 (unch)
Navidea's Macrophage Therapeutics Gets A $2.5 Million Vote Of Confidence
Basileus - at Seeking Alpha - Tue Feb 03, 1:57PM CST
NAVB: 1.60 (unch)
Navidea to report preliminary results next Monday
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:06PM CST
NAVB: 1.60 (unch)
Navidea to Report Preliminary 2014 Revenue and Present at BIO CEO & Investor Conference February 9
Business Wire - Mon Feb 02, 2:17PM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced that the Company will report preliminary fourth quarter and full year 2014 revenues and provide a business update before market open on Monday, February 9, 2015. In addition, Rick Gonzalez, Chief Executive Officer, will present at the 17th Annual BIO CEO and Investor Conference at 10:00 am EST on February 9, 2015.
NAVB: 1.60 (unch)
Lymphoseek(R) Performance vs. Sulfur Colloid in Breast Cancer Patients Published in Annals of Surgical Oncology; Fewer Nodal Dissections Required
Business Wire - Thu Jan 29, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that an analysis comparing sentinel lymph node (SLN) biopsy procedures using Lymphoseek(R) (technetium Tc 99m tilmanocept) injection (TcTM) + vital blue dye (VDB) to filtered [(99m)Tc] sulfur colloid (fTcSC) + VBD in breast cancer patients was published in the Annals of Surgical Oncology. Results demonstrated the following:
NAVB: 1.60 (unch)
Seeking Alpha's Biotech Weekly: Salix Sale Murmurs, A Very Active CHMP, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jan 23, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CRIS: 3.23 (+0.25), NAVB: 1.60 (unch), TROV: 4.99 (-0.17), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), ABBV: 58.05 (+1.00), ARIA: 7.35 (+0.45), ARNA: 4.55 (+0.02), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Navidea sets up financing for therapeutics subsidiary
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 7:11AM CST
NAVB: 1.60 (unch)
Navidea's Macrophage Therapeutics Unit Announces Plan for $2.5 Million Financing
Business Wire - Wed Jan 21, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced it has entered into a non-binding term sheet for an initial round of standalone financing for its Macrophage Therapeutics business unit, which will be incorporated as a subsidiary of Navidea, known as Macrophage Therapeutics, Inc. The initial investment in Macrophage Therapeutics is being proposed by Navidea Director and newly named Macrophage Therapeutics Chief Executive Officer, Michael Goldberg, M.D., who intends to lead a small group of accredited investors to complete the financing.
NAVB: 1.60 (unch)
Navidea Biopharmaceuticals to Present at Biotech Showcase 2015
Business Wire - Tue Jan 06, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents, today announced that Rick Gonzalez, Chief Executive Officer, will present at the Biotech Showcase 2015, taking place in San Francisco, CA, on Tuesday, January 13th at 2:30 PM PT (5:30 PM ET) in the "Mission I" room of the Parc 55 Wyndham in Union Square.
NAVB: 1.60 (unch)
Navidea adds management talent
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 7:49AM CST
NAVB: 1.60 (unch)
Navidea Strengthens Leadership Team to Accelerate Lymphoseek(R) Growth
Business Wire - Mon Jan 05, 6:30AM CST
Navidea Biopharmaceuticals (NYSE MKT:NAVB) today announced that it has strengthened its management team with the appointments of Thomas J. Klima as Senior Vice President and Chief Commercial Officer and Michael Tomblyn, M.D., M.S. as Executive Medical Director. These highly experienced and skilled additions to the Company's team are being made to support the continued emphasis on the growth of Lymphoseek(R) (technetium Tc 99m tilmanocept) injection.
NAVB: 1.60 (unch)
Navidea Pharmaceuticals: An Update On My $2 Biotech Lottery Ticket
Bret Jensen - at Seeking Alpha - Tue Dec 23, 9:27AM CST
NAVB: 1.60 (unch)
Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma
PR Newswire - Thu Dec 18, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Geron Corporation (NASDAQ: GERN), PDL BioPharma Inc. (NASDAQ: PDLI), Cytori Therapeutics Inc. (NASDAQ: CYTX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, December 17, 2014, surged as the Dow Jones Industrial Average finished at 17,356.87, up 1.69% and the NASDAQ Composite closed at 4,644.31, up 2.12%. The S&P 500 finished the session 2.04% higher at 2,012.89. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Index ended the day at 791.66, up 1.90%, with the index advancing 6.28% in the previous three months. Register for your complimentary reports on these five stocks at:
NAVB: 1.60 (unch), CYTX: 0.47 (unch), GERN: 3.03 (unch), ARIA: 7.35 (+0.45), PDLI: 7.28 (+0.03)
Can the Rally in Navidea (NAVB) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:40AM CST
Can the Rally in Navidea (NAVB) Shares Continue?
NAVB: 1.60 (unch)
Data Presented by Independent Academic Collaborators Demonstrate Ability of Novel Manocept(TM) Immunotherapy to Kill Activated Macrophages from KS Patients
Business Wire - Mon Dec 15, 12:09PM CST
Macrophage Therapeutics, a newly created business unit of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), hosted a conference where data was presented using Manocept(TM) platform compound, tilmanocept, that was generated by independent academic collaborators with expertise in the HIV/AIDS, cancer, tuberculosis (TB), rheumatoid arthritis and cardiovascular disease therapeutic areas. The technical presentations highlighted tilmanocept's ability to target activated macrophages implicated in pathology. Specifically data were presented in:
NAVB: 1.60 (unch)
Macrophage Therapy Is Navidea's Value Driver
Ugly Duckling - at Seeking Alpha - Mon Dec 15, 2:31AM CST
NAVB: 1.60 (unch)
Macrophage Therapeutics to Present Data Supporting Potential for Breakthrough with Manocept(TM) in Immunotherapy
Business Wire - Fri Dec 12, 11:20AM CST
Macrophage Therapeutics, a newly created business unit of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), is pleased to present at a conference data generated by independent academic collaborators that it believes represent a pathway to a potential major scientific breakthrough in disease therapy, and more specifically, immunotherapy. Data will be presented to members of the scientific and investment communities both live in New York City and via webinar (details below).
NAVB: 1.60 (unch)
Navidea Forms Macrophage Therapeutics Business Unit to Explore Therapeutic Applications of Manocept(TM)
Business Wire - Wed Dec 10, 6:30AM CST
Navidea Biopharmaceuticals (NYSE MKT: NAVB) announced today the formation of a new business unit, Macrophage Therapeutics, to further explore therapeutic applications for the Manocept(TM) platform. The Manocept platform serves as the molecular backbone of Navidea's FDA-approved, activated macrophage-targeting agent, Lymphoseek(R) (technetium Tc 99m tilmanocept) injection. Preclinical data being developed by the Company using tilmanocept linked to various therapeutic agents suggest that tilmanocept's binding affinity to CD206 receptors demonstrates the potential for this technology to be useful in treating diseases linked to the over-activation of macrophages. This includes various cancers as well as autoimmune, infectious, cardiovascular, and central nervous system diseases.
NAVB: 1.60 (unch)
Achillion Soars on 6 Week HCV Cure When Used with Gilead's Sofosbuvir - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Feb 09, 2:38PM CST
Achillion shares are up nearly double digits today thanks to promising results for its ACH-3102 when used in combination with Gilead Sciences' (GILD) sofosbuvir.
NAVB: 1.60 (unch), AUPH: 3.46 (+0.01), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20)
Navidea reports preliminary 2014 revenue
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 7:07AM CST
NAVB: 1.60 (unch)
Navidea Reports Preliminary 2014 Revenue; Provides Update on New Commercial Strategy
Business Wire - Mon Feb 09, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today reports preliminary, unaudited total revenue of $6.3 million for the year ended December 31, 2014, including total product revenue from Lymphoseek(R) (technetium Tc 99m tilmanocept) injection of $4.2 million. For the three months ended December 31, 2014, Navidea reports preliminary, unaudited total revenue of $2.2 million, including total product revenue from Lymphoseek of $1.5 million. Total revenue includes product revenue from sales of Lymphoseek to the Company's distribution partner, grant revenue and revenue generated from business development activities; however, it should be noted product revenue recognized by Navidea represents only a portion of the total brand revenue generated by the distribution partner on sales of Lymphoseek to end customers. Navidea's gross profit is expected to be $4.7 million for the year ended December 31, 2014 and $1.9 million for the three months ended December 31, 2014.
NAVB: 1.60 (unch)
Navidea's Macrophage Therapeutics Gets A $2.5 Million Vote Of Confidence
Basileus - at Seeking Alpha - Tue Feb 03, 1:57PM CST
NAVB: 1.60 (unch)
Navidea to report preliminary results next Monday
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:06PM CST
NAVB: 1.60 (unch)
Navidea to Report Preliminary 2014 Revenue and Present at BIO CEO & Investor Conference February 9
Business Wire - Mon Feb 02, 2:17PM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced that the Company will report preliminary fourth quarter and full year 2014 revenues and provide a business update before market open on Monday, February 9, 2015. In addition, Rick Gonzalez, Chief Executive Officer, will present at the 17th Annual BIO CEO and Investor Conference at 10:00 am EST on February 9, 2015.
NAVB: 1.60 (unch)
Lymphoseek(R) Performance vs. Sulfur Colloid in Breast Cancer Patients Published in Annals of Surgical Oncology; Fewer Nodal Dissections Required
Business Wire - Thu Jan 29, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that an analysis comparing sentinel lymph node (SLN) biopsy procedures using Lymphoseek(R) (technetium Tc 99m tilmanocept) injection (TcTM) + vital blue dye (VDB) to filtered [(99m)Tc] sulfur colloid (fTcSC) + VBD in breast cancer patients was published in the Annals of Surgical Oncology. Results demonstrated the following:
NAVB: 1.60 (unch)
Seeking Alpha's Biotech Weekly: Salix Sale Murmurs, A Very Active CHMP, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jan 23, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CRIS: 3.23 (+0.25), NAVB: 1.60 (unch), TROV: 4.99 (-0.17), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), ABBV: 58.05 (+1.00), ARIA: 7.35 (+0.45), ARNA: 4.55 (+0.02), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Navidea sets up financing for therapeutics subsidiary
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 7:11AM CST
NAVB: 1.60 (unch)
Navidea's Macrophage Therapeutics Unit Announces Plan for $2.5 Million Financing
Business Wire - Wed Jan 21, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced it has entered into a non-binding term sheet for an initial round of standalone financing for its Macrophage Therapeutics business unit, which will be incorporated as a subsidiary of Navidea, known as Macrophage Therapeutics, Inc. The initial investment in Macrophage Therapeutics is being proposed by Navidea Director and newly named Macrophage Therapeutics Chief Executive Officer, Michael Goldberg, M.D., who intends to lead a small group of accredited investors to complete the financing.
NAVB: 1.60 (unch)
Navidea Biopharmaceuticals to Present at Biotech Showcase 2015
Business Wire - Tue Jan 06, 6:30AM CST
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents, today announced that Rick Gonzalez, Chief Executive Officer, will present at the Biotech Showcase 2015, taking place in San Francisco, CA, on Tuesday, January 13th at 2:30 PM PT (5:30 PM ET) in the "Mission I" room of the Parc 55 Wyndham in Union Square.
NAVB: 1.60 (unch)
Navidea adds management talent
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 7:49AM CST
NAVB: 1.60 (unch)
Navidea Strengthens Leadership Team to Accelerate Lymphoseek(R) Growth
Business Wire - Mon Jan 05, 6:30AM CST
Navidea Biopharmaceuticals (NYSE MKT:NAVB) today announced that it has strengthened its management team with the appointments of Thomas J. Klima as Senior Vice President and Chief Commercial Officer and Michael Tomblyn, M.D., M.S. as Executive Medical Director. These highly experienced and skilled additions to the Company's team are being made to support the continued emphasis on the growth of Lymphoseek(R) (technetium Tc 99m tilmanocept) injection.
NAVB: 1.60 (unch)
Navidea Pharmaceuticals: An Update On My $2 Biotech Lottery Ticket
Bret Jensen - at Seeking Alpha - Tue Dec 23, 9:27AM CST
NAVB: 1.60 (unch)
Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma
PR Newswire - Thu Dec 18, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Geron Corporation (NASDAQ: GERN), PDL BioPharma Inc. (NASDAQ: PDLI), Cytori Therapeutics Inc. (NASDAQ: CYTX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, December 17, 2014, surged as the Dow Jones Industrial Average finished at 17,356.87, up 1.69% and the NASDAQ Composite closed at 4,644.31, up 2.12%. The S&P 500 finished the session 2.04% higher at 2,012.89. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Index ended the day at 791.66, up 1.90%, with the index advancing 6.28% in the previous three months. Register for your complimentary reports on these five stocks at:
NAVB: 1.60 (unch), CYTX: 0.47 (unch), GERN: 3.03 (unch), ARIA: 7.35 (+0.45), PDLI: 7.28 (+0.03)
Can the Rally in Navidea (NAVB) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:40AM CST
Can the Rally in Navidea (NAVB) Shares Continue?
NAVB: 1.60 (unch)
Data Presented by Independent Academic Collaborators Demonstrate Ability of Novel Manocept(TM) Immunotherapy to Kill Activated Macrophages from KS Patients
Business Wire - Mon Dec 15, 12:09PM CST
Macrophage Therapeutics, a newly created business unit of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), hosted a conference where data was presented using Manocept(TM) platform compound, tilmanocept, that was generated by independent academic collaborators with expertise in the HIV/AIDS, cancer, tuberculosis (TB), rheumatoid arthritis and cardiovascular disease therapeutic areas. The technical presentations highlighted tilmanocept's ability to target activated macrophages implicated in pathology. Specifically data were presented in:
NAVB: 1.60 (unch)
Macrophage Therapy Is Navidea's Value Driver
Ugly Duckling - at Seeking Alpha - Mon Dec 15, 2:31AM CST
NAVB: 1.60 (unch)
Macrophage Therapeutics to Present Data Supporting Potential for Breakthrough with Manocept(TM) in Immunotherapy
Business Wire - Fri Dec 12, 11:20AM CST
Macrophage Therapeutics, a newly created business unit of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), is pleased to present at a conference data generated by independent academic collaborators that it believes represent a pathway to a potential major scientific breakthrough in disease therapy, and more specifically, immunotherapy. Data will be presented to members of the scientific and investment communities both live in New York City and via webinar (details below).
NAVB: 1.60 (unch)
Navidea Forms Macrophage Therapeutics Business Unit to Explore Therapeutic Applications of Manocept(TM)
Business Wire - Wed Dec 10, 6:30AM CST
Navidea Biopharmaceuticals (NYSE MKT: NAVB) announced today the formation of a new business unit, Macrophage Therapeutics, to further explore therapeutic applications for the Manocept(TM) platform. The Manocept platform serves as the molecular backbone of Navidea's FDA-approved, activated macrophage-targeting agent, Lymphoseek(R) (technetium Tc 99m tilmanocept) injection. Preclinical data being developed by the Company using tilmanocept linked to various therapeutic agents suggest that tilmanocept's binding affinity to CD206 receptors demonstrates the potential for this technology to be useful in treating diseases linked to the over-activation of macrophages. This includes various cancers as well as autoimmune, infectious, cardiovascular, and central nervous system diseases.
NAVB: 1.60 (unch)
